PHGUF: Assets Multiplying Like Rabbits; $20 Million Check in the Bank Soon
Print Friendly
Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. from Roth Capital Partners is published.
Pharming announced the acquisition of assets from Transgenic Rabbit Models SASU (TRM) for €0.5 million in cash. Through this acquisition, PHGUF has access to five recombinant human product candidates for Pompe’s disease, Gaucher’s Disease, Fabry’s disease and Haemophilia A and B. Additionally, PHGUF gained access to the transgenic rabbit founder technology of TRM. This acquisition strengthens PHGUF’s position in the human recombinant market and adds potential new products alongside Ruconest. Reiterate Buy.
Click Here For Print Version of Full Report (Adobe Acrobat Required)
Click Here For Full Report in HTML (for mobile users)
About ROTH Capital Partners
ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in San Diego, Los Angeles, Seattle, New York and Pennsylvania. International offices include a Shanghai Representative Office and a Hong Kong Limited Office.
Contact
Sijmen de Vries, CEO: T: +31 524 7400
“This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature”